Arq's PAC-for-PFAS Pivot: Lower-Cost Compliance Play Could Rewrite the GAC Optionality Math

Despite a soft seasonal quarter, ARQ delivered a 520bps gross margin expansion and unveiled a near-term PFAS product that may sidestep the $40–60M GAC capex decision entirely.

ARQ · Earnings Call · 2026-08-11

A Quietly Powerful Quarter

Arq’s Q2 2026 results were, on their face, incremental — revenue of ~$30M, up modestly, and adjusted EBITDA of $5.8M versus $3.7M a year ago. But the underlying message was far stronger. “This quarter is a clear demonstration of the earnings power of our PAC business.” — Robert Rasmus, Chief Executive Officer · 2026-08-11 The PAC for PFAS product launch, coupled with the company's assertion that it can grow EBITDA by up to 50% without any GAC contribution, fundamentally reframes the investment thesis. Gross margin rose to approximately 38.5%, up roughly 520 basis points, with a 34.2% trailing gross margin still reflecting the drag from prior GAC ramp-up. The company also confirmed that the April plant turnaround — a potentially disruptive event — was completed under budget and fully capitalized.

The PAC-for-PFAS Strategy

The centerpiece of the call was the introduction of a new powdered activated carbon line designed specifically for PFAS removal. The company argues that many water companies that are marginally above the 4 parts per trillion regulatory threshold can achieve compliance using this product with existing infrastructure, avoiding the heavy capital expenditure of granular activated carbon systems. As CEO Bob Rasmus explained, “What PAC for PFAS does for a certain segment of the market that is close to but not currently in compliance, they can use our PAC for PFAS product to get them into compliance.” — Robert Rasmus, Chief Executive Officer · 2026-08-11 Management anticipates pricing and margins substantially above baseline PAC, and initial customer trials are underway with meaningful contribution expected in 2027. This is a strategically astute move. It directly attacks the compliance timeline (monitoring starts April 2027) while preserving the optionality of the bituminous GAC plant. It also aligns with the company's desire to grow PFAS opportunity without betting the balance sheet. The product is described as an interim or permanent solution for a meaningful segment of the market, and management believes it is "fairly unique" in this offering. While no material 2026 revenue is expected, the potential to diversify the bituminous-based GAC strategy with a higher-margin, faster-to-market product is a genuine change in narrative.

GAC: Discipline Over Ambition

The GAC update was equally important. Management now guides capital expenditure for Phase 1 (25 million pounds) at $40–60 million, based on two independent engineering designs. Crucially, they stress that no final investment decision has been made.

We are not going to invest this kind of capital until we know it will generate a return that justifies the investment.
Robert Rasmus, Chief Executive Officer · 2026-08-11

This is a marked shift from previous quarters where management expressed near-certainty about proceeding. On the March 2026 call, Rasmus stated: “I don't see any reasonable alternative other than... we would go forward because the market fundamentals are so great.” — Robert Rasmus, Chief Executive Officer · 2026-03-10 Now the tone is one of optionality and capital discipline, with the company explicitly guiding to no bituminous GAC sales or production in 2027. That conservative posture is likely a welcome relief for shareholders who have watched the GAC plant rack up cost overruns and delays. The decision to pivot toward PAC for PFAS while keeping the GAC option alive is a rational de-risking. It also gives management time to secure lower-cost financing, perhaps through debt rather than equity. As CFO Shimon Steinmetz noted, the company has already identified non-people-related cost reductions and is exploring enhancements to its credit facility.

Valuation Mismatch and the Path Forward

Rasmus closed the call by emphasizing the disconnect between the company's operational trajectory and its valuation. “We have transformed ARC so that our growth is not reliant on granular activated carbon... trading at a multiple less than 5x this year's guidance and approximately 3x our $30 million goal.” — Robert Rasmus, Chief Executive Officer · 2026-08-11 That $30 million EBITDA goal — a 50% increase from 2026 guidance — is now driven by PAC volume, pricing, cost takeout, and new products, not GAC. The market may be slow to credit this because of the lingering overhang of the failed GAC ramp-up. Yet the valuation has compressed even as the business has demonstrably improved. Balance sheet remains tight — unrestricted cash was $1M at June 30 (though $3M by July 1) and total debt of $30.9M — but the company maintains it is not constrained by its credit facility.

What Changed?

The fundamental change is that Arq has decoupled its growth narrative from the capital-intensive, delayed GAC project. The Corbin asset monetization (asphalt, rare earth, etc.) adds further optionality. In a single quarter, the company went from "we must build GAC" to "we can grow 50% without GAC, and if we do build it, we'll do so on our terms." That is a meaningful re-rating catalyst, and the $40–60M capex estimate, coupled with the PAC-for-PFAS product, gives investors a clearer framework for the range of outcomes. Whether the market embraces this shift remains to be seen, but the evidence this quarter argues that Arq is no longer at the mercy of a single project's execution.